Curriculum Vitae Eva Maria König, PhD

PERSONAL DATA

Name	**Eva Maria König, née Putz**
Citizenship	Austria
Current work address	Medical University of Vienna, Center for Physiology and Pharmacology Institute of Pharmacology, Waehringer Strasse 13A, A-1090 Vienna, Austria
ORCID	https://orcid.org/0000-0002-9990-4477
Homepage	https://evamkoenig727.wixsite.com/putz-koenig-lab
E-mail	eva-maria.koenig@meduniwien.ac.at

FIELDS OF RESEARCH

Keywords	immunology, tumor immunology, cell biology, natural killer (NK) cells, immunoediting, tumor evolution, cytokines, JAK/STAT/SOCS signaling, pharmacology, extracellular matrix, invasion and metastasis, leukemia, melanoma, cellular immunotherapy

EDUCATION

2007-2013	PhD thesis (N094) at the Medical University of Vienna (MUW) under the supervision of Univ.-Prof. Dr. V. Sexl: Impact of IFNAR1 and STAT1-S727 on NK cell activity and tumor surveillance
2006-2007	Diploma thesis at the Max Perutz Laboratories, Vienna, under the supervision of a.o.Univ.-Prof. Dr. F. Pittner: Studies to develop a meat freshness sensor based on nanotechnology
2001-2007	Diploma studies of Chemistry at the University of Vienna
1994 – 2001	High school BG Bregenz Blumenstraße

EMPLOYMENTS

2024 – current	Principal Investigator at the Institute of Pharmacology, MUW, Vienna
2019 – 2023	Principal Investigator at the St. Anna Children's Cancer Research Institute, Vienna
Apr. 2017 – Mar. 2018	Max Perutz Laboratories / Vetmeduni Vienna (Austria): Post-doctoral fellow in the laboratories of Prof. Thomas Decker (MFPL) and Prof. Veronika Sexl (Vetmeduni)
Mar. 2015 – Feb. 2017	QIMR Berghofer Institute of Medical Research (QLD, Australia): Post-doctoral fellow in the laboratory of Prof. Mark Smyth
Sept. 2013 – Feb. 2015	Vetmeduni Vienna (Austria): Post-doctoral fellow in the laboratory of Prof. Dr. V. Sexl
2007-2013	MUW/Vetmeduni Vienna (Austria): Pre-doctoral fellow in the laboratory of Prof. Dr. V. Sexl, supervision of trainees and diploma students
Sept.-Oct. 2005	Tecnonuclear (Buenos Aires, Argentina): internship

ACADEMIC RECOGNITION

Grants	2024: DOC fellowship for my PhD student Faith David, Austrian Academy of Sciences (98,160 €; "The role of serine/threonine kinase 38 (STK38(L)) in NK cells – A promising novel target for cancer immunotherapy", 09/2024-07/2026; PhD and project supervision) 2021: Stand-Alone Project, Austrian Science Fund (FWF P34832; 399,640 €; "Non-canonical STAT1 signaling in natural killer cells"; 01/2022-06/2027; project lead) 2021: Fellinger Cancer Research Grant (25,000 €, "Uncovering immune evasion mechanisms of leukemic cells from natural killer cells", 07/2021-06/2022, project lead) 2021: DOC fellowship for my PhD student Michelle Buri, Austrian Academy of Sciences (115,500 €; "How do leukemic cells escape natural killer cell-mediated surveillance? Uncovering novel immune evasion mechanism(s)"; 08/2021-06/2024; PhD and project supervision) 2019: Science Communication Project, Austrian Science Fund (FWF WKP 132-B: 49,083 €; "Art4Science", 05/2020-04/2022, project lead) 2018: Stand-Alone Project, Austrian Science Fund (FWF P32001-B; 341,760 €; "Finding tumor immune evasions strategies by cellular barcoding"; 03/2019-09/2023, project lead) 2014: Erwin Schrödinger Fellowship, Austrian Science Fund (FWF J3635; 156,940 €; "NLRP1 and NLRP3 in T and NK cell immunity"; 02/2015-03/2018, project lead) 2008: DOC-fFORTE, Austrian Academy of Science (60,000 €; "STAT1 Serine727 – Key Regulator for NK Cell-Mediated Cytotoxicity and Tumor Surveillance"; 01/2010-12/2011; project lead)
Awards	2022: Heribert-Konzett-Prize of the Austrian Pharmacological Society (APHAR) 2022: Best talk at the 14th ÖGMBT Annual Meeting, Vienna, Austria 2014: Poster prize at the 6th ÖGMBT Annual Meeting, Vienna, Austria 2014: Armin Tschermak von Seysenegg Prize, Gesellschaft der Freunde der VUW 2013: EFIS scholarship, 2nd Meeting of Mid-Europ. Soc. f. Immunol. and Allergol., Croatia 2011: EFIS-EJI scholarship for EMBO - Signaling in the Immune System Meeting in Siena, Italy 2009: Poster prize at the Natural Killer Cell Symposium in Freiburg, Germany
Oral Presentations (excerpt)	2025: - Hearing for a professorship in "Animal Physiology" at the University of Salzburg, Austria 2024: - Series "Being up to date in cancer biology" at the VetMedUni Vienna, Austria 2023: - Seminar at the Fondazione Ri.MED, Palermo, Italy - Hearing for a professorship in "Cell Biology" at the Karl Landsteiner University, Krems, Austria - CACB Seminar at the Center for Anatomy and Cell Biology, MUW, Austria 2022: - Keynote lecture at the 26th Annual Meeting of the APHAR in Graz, Austria - 14th ÖGMBT Meeting, Vienna, Austria - Series "Being up to date in cancer biology" at the VetMedUni Vienna, Austria 2021: Karl Landsteiner Lunchtime seminar, virtual 2020: Science Meeting at the Institute of Physiology, Medical University of Vienna, Austria 2019: LBI for Hematology and Oncology KickOff Meeting, Austria 2014: NK2014 Meeting, Germany 2013: - 2nd Meeting of Middle-Europ. Soc. f. Immunol. & Allergol. Croatia - 19th Scientific Symposium of APHAR, Austria 2010: Meeting of the Austrian Society for Allergology and Immunology (ÖGAI), Vienna, Austria
Memberships	APHAR (Austrian Pharmacological Society, since 2008) EATI (European Academy of Tumor Immunology, since 2016) OEGAI (Austrian Society for Allergology and Immunology, since 2011) OEGHO (Austrian Society of Hematology and Medical Oncology, since 2024) OEGMBT (Austrian Association of Molecular Life Sciences and Biotechnology, since 2013)
Peer-Review activities	*Journals:* Animal Biotechnology, Cancer Research, Frontiers in Immunology, Journal of ImmunoTherapy of Cancer, Journal of Medicinal Chemistry, Molecules, Nature Communications, OncoImmunology, PlosOne, Trends in Immunology; *Funding Bodies:* Children's Cancer and Leukaemia Group (CCLG), Grace Kelly Childhood Cancer Trust
Editorial activities	2021-2022: Topic editor of "Drivers of Innate Lymphoid Cell Plasticity" in Frontiers in Immunology
Collaboration partners	Emilio Casanova, Matthias Farlik, Thorsten Füreder, Dietmar Herndler-Brandstetter, Johannes Huppa, Xaver König, Christoph Minichsdorfer, Herwig Moll, Shinya Sakaguchi, Isabella Salzer, Gernot Schabbauer, Iris Uras-Jodl, Charlotte Zajc, Eva Zebedin-Brandl (MUW, Austria); Manfred Lehner, Sabine Strehl, George Cresswell, etc. (CCRI, Austria); Dagmar Gotthardt, Veronika Sexl (Vetmeduni, Austria); Dagmar Stoiber-Sakaguchi, Agnieszka Witalisz-Siepracka (KL University Krems, Austria); Anna Obenauf (IMP, Austria); Michael Traxlmayr (BOKU, Austria); Tobias Bald, Dillon Corvino (University of Bonn, Germany); Leila Perié (Institut Curie, France); Ton Schumacher (NKI, The Netherlands); Heidi Harjunpää (University of Helsinki, Finland); Eric Kowarz, Rolf Marschalek (University of Frankfurt, Germany); Martin Distel (Huntsman Cancer Institute, Utah, USA); Melissa Elliott, Todd A. Fehniger (Washington University in St. Louis, USA); Debby Hynx, Fengyuan Tang (University of Basel, Switzerland); Juming Yan (Xuzhou Medical University, China)

SCIENCE COMMUNICATION ACTIVITIES

Science Communication	since 2020: Art4Science project (https://www.art4science.at/) 2019-2023: Lange Nacht der Kinderkrebsforschung, CCRI 2018: BE OPEN Science & Society Festival of the FWF
Teaching	Since 2024: MUW: Block 7 (SE in "Science and Medicine"), Block 4 (SE in "Functional systems and biological regulation"), Basic lecture in the PhD program MolSignTrans (VO), Journal Clubs (SE), Thesis Seminars (SE) 2020 WS: MUW: Spot Lights on Paediatric Cancer Research (SE) 2017 SS: Vetmeduni Vienna: "New therapeutic approaches in tumor therapies" (SE) 2016: QIMR Berghofer Institute, Australia: High school work experience program (SE+PR) 2014 WS: MUW: Basic lecture in the PhD program Inflammation and Immunity (VO) 2007 SS: University of Vienna: Laboratory Course C + Molecular Biology II (PR)
Supervision	Bachelor student: L. Sippl (2023) Master students: K. Kos (2016), S. Stofner (2021), A. Dupanovic (2023), N. Schindler (2024), A. Borojević (2025), K. Kiss (2025) PhD students: M.C. Buri (2020-2025), F.O. David (2021-current) (MUW, N094) Postdoctoral fellows: Dr. H. Baik (2019-2023), Dr. F. Hall-Glenn (2021), Dr. B. Kovacic (2019-2020)
Meetings – Poster Presentations (excerpt)	2025: International Congress of Immunology (ICI), Vienna, Austria: M.C. Buri, A. Borojević, M.R. Shoeb, A. Bykov, P. Repiscak, A. Dupanovic, F.O. David, F. Halbritter, E.M. Putz. "Revealing novel evasion mechanisms of leukemic cells from natural killer cells" 2016: International Congress of Immunology (ICI), Melbourne, Australia: E.M. Putz, F. Souza-Fonseca-Guimaraes, D.S. Barkauskas, L. Town, M.D. Hulett, M.J. Smyth. "The role of heparanase in NK cell migration and NK cell-mediated tumour surveillance" 2015: Immunotherapy@Brisbane, Brisbane, Australia: E.M. Putz, F. Souza-Fonseca-Guimaraes, D.S. Barkauskas, L. Town, M.D. Hulett, M.J. Smyth. "The role of heparanase in NK cell migration and NK cell-mediated tumour surveillance" 2015: 1st Australian Innate Lymphocyte Symposium, Melbourne, Australia: E.M. Putz, A. Majoros, D. Gotthardt, T. Decker and V. Sexl. "Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity" 2012: Natural Killer cell Symposium NK2012, Heidelberg, Germany: E.M. Putz, D. Gotthardt, D. Stoiber, T. Decker and V. Sexl, "Stat1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance" 2011: EMBO Conference: Signaling in the Immune System, Siena, Italy: E.M. Putz, E.M. Zebedin-Brandl, M. Prchal, T. Decker and V. Sexl, "STAT1 Serine727 – License to Kill" 2009: Natural Killer cell Symposium NK2009, Freiburg, Germany: E.M. Putz, E.M. Zebedin, A. Csiszar, M. Prchal, T. Decker, P. Kovarik and V. Sexl, "STAT1-Serine727 – Key regulator for NK cell mediated cytotoxicity and tumor surveillance" 2009: 15th International Summer School on Immunology (FEBS), Hvar, Croatia: E.M. Putz, E. Zebedin, A. Csiszar, M. Prchal, A. Berger, T. Decker, P. Kovarik and V. Sexl, "STAT1-S727 - Key regulator for NK cell-mediated cytotoxicity and tumor surveillance"

MAIN AREAS OF RESEARCH

For the last 18 years, I have worked in the field of tumor immunology, starting as a PhD student in the laboratory of Veronika Sexl (MUW and Vetmeduni Vienna) and proceeding as a postdoctoral fellow in the laboratory of Mark Smyth at the QIMR Berghofer Institute of Medical Research in Brisbane (Australia). In 2019 I kicked of my independent research lab at the St. Anna Children's Cancer Research Institute (CCRI) and in 2024 we moved to the MUW in Vienna, Austria.

The focus of my studies has always been to increase our knowledge about how to improve the anti-tumor functions of cytotoxic immune cells such as natural killer and T cells. By using gene-modified mice, a multitude of *in vivo* tumor models and an extensive range of *in vitro* assays (e.g. multi-color flow cytometry, molecular biology and functional assays, cellular barcoding, primary cell transduction, gene knockdown and knockout, mass spectrometry, etc.) I have contributed to the discovery of exciting novel ways of enhancing NK cell-mediated tumor surveillance (e.g. blocking CDK8-mediated STAT1-S727 phosphorylation or CIS-mediated downregulation of IL-15 signaling) and highlighted the potential drawback of drugs that interfere with NK cell migration (heparanase inhibitors) or T cell function (PI3Kδ inhibitors).

I collaborated with highly ranked scientists all over the world and published 1 book chapter, 6 reviews and 35 original peer-reviewed papers, some of which had to be corrected or retracted due to concerns of data fabrication by Mark J. Smyth. Please see **here** for more information and be assured that I had no part in scientific misconduct at any time.

PUBLICATIONS (published under my maiden's name E.M. Putz)

1. X. Ju*, E.M. Putz*, Y. Liu, D. Yuan, G. Sun, S. Koda, Z. Fu, S. Shao, C. Tong, B. Deng, J. Hu, J. Yan. Metabotropic glutamate receptor 4-mediated glutamatergic signaling reshapes the tumor microenvironment by regulating dendritic cell maturation. ***Nature Communications***, *PMID: 40593670*, Jul. 2025
2. M.C. Buri, M.R. Shoeb, A. Bykov, P. Repiscak, H. Baik, A. Dupanovic, F.O. David, B. Kovacic, F. Hall-Glenn, S. Dopa, J. Urbanus, L. Sippl, S. Stofner, D. Emminger, J. Cosgrove, D. Schinnerl, A.R. Poetsch, M. Lehner, X. Koenig, L. Perié, T.N. Schumacher, D. Gotthardt, F. Halbritter, E.M. Putz. Natural killer cell-mediated cytotoxicity shapes the clonal evolution of B cell leukaemia. ***Cancer Immunology Research***, *PMID: 39642167*, Mar. 2025
3. J. Zehenter*, M. Prchal-Murphy*, M. Fischer, A. Pirabe, M. Themanns, B. Afrashteh, E.M. Putz, K. Kollmann, J. Basilio, M. Salzmann, W. Strohmaier, G. Krumpl, A. Farr, V. Sexl, M. Freissmuth, E.M. Zebedin-Brandl. Repurposing the prostaglandin analogue treprostinil and the calcium-sensing receptor modulator cinacalcet to revive cord blood as an alternate source of hematopoietic stem and progenitor cells for transplantation. ***Frontiers in Pharmacology***, *PMID: 39850556,* Jan. 2025
4. A. Witalisz-Siepracka, C.-M. Denk, B. Zdársky, L. Hofmann, S. Edtmayer, T. Harm, S. Weiss, K. Heindl, M. Hessenberger, S. Summer, S. Dutta, E. Casanova, G.J. Obermair, B. Györffy, E.M. Putz, H. Sill and D. Stoiber. STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance. ***Frontiers in Immunology***, *PMID: 39034990*, Jul. 2024
5. J. List, J. Gattringer, S. Huszarek, S. Marinovic, H.A. Neubauer, P. Kudweis, E.M. Putz, R. Hellinger, D. Gotthardt. Boosting the anti-tumor activity of natural killer cells by caripe 8 - A Carapichea ipecacuanha isolated cyclotide. ***Biomedicine & Pharmacotherapy***, *PMID: 38976957*, Jul. 2024
6. E. Lilliu*, B. Hackl*, E. Zabrodska, S. Gewessler, T. Karge, J. Marksteiner, J. Sauer, E.M. Putz, H. Todt, K. Hilber, X. Koenig. Cell size induced bias of current density in hypertrophic cardiomyocytes. ***Channels***, *PMID: 38836323*, Jun./Dec. 2024
7. I.M. Saldana-Guerrero*, L.F. Montano-Gutierrez*, K. Boswell, C. Hafemeister, E. Poon, L.E. Shaw, D. Stavish, R.A. Lea, S. Wernig-Zorc, E. Bozsaky, I.S. Fetahu, P. Zoescher, U. Pötschger, M. Bernkopf, A. Wenninger-Weinzierl, C. Sturtzel, C. Souilhol, S. Tarelli, M.R. Shoeb, P. Bozatzi, M. Rados, M. Guarini, M.C. Buri, W. Weninger, E.M. Putz, M. Huang, R. Ladenstein, P.W. Andrews, I. Barbaric, G.D. Cresswell, H.E. Bryant, M. Distel, L. Chesler, S. Taschner-Mandl, M. Farlik, A. Tsakiridis, F. Halbritter. ***Nature Communications***, *PMID: 38702304*, May 2024
8. D. Yuan, J. Hu, X. Ju, E.M. Putz, S. Zheng, G. Sun, S. Koda, Z. Xu, W. Nie, S. Shao, Y. Chen, R. Tang, K.-Y. Zheng, J. Yan. NMDAR antagonists suppressed tumor progression by regulating tumor-associated macrophages. ***PNAS****, PMID: 37967215, Nov. 2023*
9. B. Hackl, E. Zabrodska, S. Gewessler, E. Liliu, E.M. Putz, A. Kiss, B. Podesser, H. Todt, R. Ristl, K. Hilber, X. Koenig. The type of suture material affects transverse aortic constriction-induced heart failure development in mice: a repeated measures correlation analysis. ***Frontiers Cardiovascular Medicine****, PMID: 37795481, Sep. 2023*
10. S. Grissenberger, C. Sturtzel, A. Wenninger-Weinzierl, B. Radic-Sarikas, E. Scheuringer, L. Bierbaumer, V. Etienne, F. Némati, S. Pascoal, M. Tötzl, E. Tomazou, M. Metzelder, E.M. Putz, D. Decaudin, O. Delattre, D. Surdez, H. Kovar, F. Halbritter, M. Distel. High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-X_L inhibition against Ewing sarcoma. ***Cancer Letters****, PMID: 36462556, Feb. 2023*
11. T. Fuereder, C. Minichsdorfer, M. Mittlboeck, C. Wagner, G. Heller, E.M. Putz, F. Oberndorfer, L. Müllauer, M.-B. Aretin, C. Czerny, U. Schwarz-Nemec. Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prespective phase I/II study. ***Oral Oncology***, *PMID: 34844042, Jan. 2022*
12. B. Salzer, C.M. Schueller, C.U. Zajc, T. Peters, M.A. Schoeber, B. Kovacic, M.C. Buri, E. Lobner, O. Dushek, J.B. Huppa, C. Obinger, E.M. Putz, W. Holter, M.W. Traxlmayr, M. Lehner. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. ***Nature Communications****, PMID: 32820173, Aug. 2020*
13. D. Prinz, K. Klein, J. List, V.M. Knab, I. Menzl, N. Leidenfrost, G. Heller, B. Polić, E.M. Putz, A. Witalisz-Siepracka, V. Sexl, D. Gotthardt. Loss of NKG2D in Murine NK Cells Leads to Increased Perforin Production Upon Long-Term Stimulation With IL-2. ***European Journal of Immunology****, PMID: 32052406, Feb. 2020*
14. D. Gotthardt, J. Trifinopoulos, V. Sexl, E.M. Putz. JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. ***Frontiers in Immunology****, PMID: 31781102, Nov. 2019*
15. E. Porpaczy*, S. Tripolt*, A. Hoelbl-Kovacic*, B. Gisslinger, Z. Bago-Horvath, E. Casanova-Hevia, T. Decker, S. Fajmann, D.A. Fux, S. Gueltekin, G. Heller, H. Herkner, T. Kolbe, E.M. Putz, C. Kornauth, M. Mueller, M. Prchal-Murphy, A.-I. Schiefer, C. Schneckenleithner, C. Skrabs, W.R. Sperr, B. Strobl, P. Valent, R. Kralovics, L. Muellauer, I. Simonitsch-Klupp, E. Cappier, E. Raffoux, J.-J. Kiladjian, M.-T. Krauth, P.B. Staber, G. Greiner, G. Hoermann, U. Jaeger*, H. Gisslinger* and V. Sexl*. Aggressive B-cell Lymphomas in Patients With Myelofibrosis Receiving JAK1/2 Inhibitor Therapy. ***Blood****, PMID: 29907599, Aug. 2018*
16. K. Nakamura, S. Kassem, A. Cleynen, M.-L. Chrétien, C. Guillerey, E.M. Putz, T. Bald, I. Förster, S. Vuckovic, G.R. Hill, S.L. Masters, M. Chesi, P.L. Bergsagel, H. Avet-Loiseau, L. Martinet* and M.J. Smyth*. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. ***Cancer Cell****, PMID: 29551594, Mar. 2018*
17. A. Witalisz-Siepracka*, D. Gotthardt*, M. Prchal-Murphy, Z. Didara, I. Menzl, D. Prinz, L. Edlinger, E.M. Putz, V. Sexl. NK cell-specific CDK8 deletion enhances antitumor responses. ***Cancer Immunology Research****, PMID: 29386186, Jan. 2018*

PUBLICATIONS (continued)

18. D. Mittal, D. Vijayan, E.M. Putz, A. Roman Aguilera, K. Markey, J. Straube, S. Kazakoff, S. Nutt, K. Takeda, G. Hill, N. Waddell, and M.J. Smyth. NK cell suppression of metastasis partially requires CD103⁺ Batf3-dependent dendritic cells and interleukin-12. ***Cancer Immunology Research,*** *PMID: 29070650, Oct. 2017*

19. E.M. Putz, A. Mayfosh, K. Kos, D.S. Barkauskas, L. Town, K.J. Goodall, D.Y. Yee, I.K.H. Poon, N. Baschuk, F. Souza-Fonseca-Guimaraes, M. Hulett* and M.J. Smyth*. Natural killer cell heparanase controls tumor invasion and immune surveillance. ***Journal of Clinical Investigations****, PMID: 28581441, June 2017,* ***Retraction,*** *Jul. 2024*

20. E.M. Putz, C. Guillerey, K. Kos, K. Stannard, K. Miles, R.B. Delconte, K. Takeda, S.E. Nicholson, N. D. Huntington, M.J. Smyth. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. ***OncoImmunology****, PMID: 28344878, Feb. 2017*

21. R. Klose, E. Krzywinska, M. Castells, D. Gotthardt, E.M. Putz, C. Kantari-Mimoun, N. Chikdene, A.K. Meinecke, K. Schrödter, I. Helfrich, J. Fandrey, V. Sexl, C. Stockmann. Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. ***Nature communications****, PMID: 27538380, Aug. 2016*

22. E.M. Putz, A. Majoros, D. Gotthardt, M. Prchal-Murphy, E.M. Zebedin-Brandl, D.A. Fux, A. Schlattl, R.D. Schreiber, S. Carotta, M. Müller, C. Gerner, T. Decker* and V. Sexl*. Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. ***OncoImmunology****, PMID: 27757297, May 2016*

23. R.B. Delconte*, T.B. Kolesnik*, L.F. Dagley*, J. Rautela, W. Shi, E.M. Putz, K. Stannard, J.G. Zhang, C. Teh, M. Firth, T. Ushiki, C. Andoniou, M.A. Degli-Esposti, P.P. Sharp, C.E. Sanvitale, G. Infusini, N.P. Liau, E.M. Linossi, C.J. Burns, S. Carotta, D.H. Gray, C. Seillet, D.S. Hutchinson, G.T. Belz, A.I. Webb, W.S. Alexander, S.S. Li, A.N. Bullock, J.J. Babon, M.J. Smyth, S.E. Nicholson*, N.D. Huntington*. CIS is a potent checkpoint in NK cell-mediated tumor immunity. ***Nature Immunology****, PMID: 27213690, May 2016;* ***Correction,*** *Dec. 2023*

24. D. Gotthardt, E.M. Putz, E. Grundschober, M. Prchal-Murphy, E. Straka, P. Kudweis, G. Heller, Z. Bago-Horvath, A. Witalisz-Siepracka, A.A. Cumaraswamy, P.T. Gunning, B. Strobl, M. Mueller, R. Moriggl, C. Stockmann, V. Sexl. STAT5 is a key regulator in NK cells and acts as molecular switch from tumor surveillance to tumor promotion. ***Cancer Discovery****, PMID: 26873347, Feb. 2016*

25. Y. Krasnova, E.M. Putz, M.J. Smyth, F. Souza-Fonseca-Guimaraes. Bench to bedside: NK cells and control of metastasis. ***Clinical Immunology****, PMID: 26476139, Oct. 2015*

26. M. Prchal-Murphy*, A. Witalisz-Siepracka*, K.T. Bednarik, E.M. Putz, D. Gotthardt, K. Meissl, V. Sexl, M. Müller, B. Strobl. *In vivo* tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. ***OncoImmunology****, PMID: 26451322, July 2015*

27. P. Pathria, D. Gotthardt*, M. Prchal-Murphy*, E.M. Putz*, M. Holcmann, M. Schlederer, B. Grabner, I. Crncec, J. Svinka, M. Musteanu, T. Hoffmann, M. Filipits, W. Berger, V. Poli, L. Kenner, M. Bilban, E. Casanova, M. Müller, B. Strobl, E. Bayer, T. Mohr, V. Sexl, R. Eferl. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. ***OncoImmunology****, PMID: 26137415, Jan. 2015*

28. E.M. Putz, D. Gotthardt, V. Sexl. STAT1-S727 - the license to kill. ***OncoImmunology****, PMID: 25941617, Dec. 2014*

29. D. Gotthardt, M. Prchal-Murphy, C. Seillet, A. Glasner, O. Mandelboim, S. Carotta, V. Sexl, E.M. Putz. NK cell development in bone marrow and liver - site matters. ***Genes & Immunity****, PMID: 25319498, Oct. 2014*

30. D. Gotthardt, E.M. Putz, E. Straka, P. Kudweis, M. Biaggio, V. Poli, B. Strobl, M. Müller, V. Sexl. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. ***Blood****, PMID: 25185262, Sept. 2014*

31. G. Hoermann, K. Blatt, G. Greiner, E.M. Putz, A. Berger, H. Herrmann, S. Cerny-Reiterer, K.V. Gleixner, C. Walz, K. Hoetzenecker, L. Müllauer, A. Reiter, K. Sotlar, V. Sexl, P. Valent, M. Mayerhofer. CD52 is a molecular target in advanced systemic mastocytosis. ***FASEB J.***, *PMID: 24760752*, *Apr. 2014*

32. E.M. Putz, M.A. Hoelzl, J. Baeck, Z. Bago-Horvath, C. Schuster, B. Reichholf, D. Kern, F. Aberger, V. Sexl, A. Hoelbl-Kovacic. Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. ***Cancers****, PMID: 24473086, Jan. 2014*

33. A. Berger, A. Hoelbl-Kovacic, J. Bourgeais, L. Hoefling, W. Warsch, E. Grundschober, I.Z. Uras, I. Menzl, E.M. Putz, G. Hoermann, C. Schuster, S. Fajmann, E. Leitner, S. Kubicek, R. Moriggl, F. Gouilleux, V. Sexl. PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. ***Leukemia****, PMID: 24263804, Nov. 2013*

34. E.M. Putz, D. Gotthardt, G. Hoermann, A. Csiszar, S. Wirth, A. Berger, E. Straka, D. Rigler, B. Wallner, A.M. Jamieson, W.F. Pickl, E. Zebedin-Brandl, M. Müller, T. Decker and V. Sexl. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. ***Cell Reports****, PMID: 23933255, Aug. 2013*

35. A.D. Köprülü, R. Kastner, S. Wienerroither, C. Lassnig, E.M. Putz, O. Majer, B. Reutterer, V. Sexl, K. Kuchler, M. Müller, T. Decker and W. Ellmeier. The Tyrosine Kinase Btk Regulates the Macrophage Response to Listeria monocytogenes Infection. ***PLoS ONE****, PMID: 23544144, Mar. 2013*

PUBLICATIONS (continued)

36. M. Prchal-Murphy*, E.M. Putz*, M. Freissmuth, V. Sexl and E. Zebedin-Brandl. Targeting PI3Kδ - One man´s meat is another man´s poison. ***OncoImmunology**, PMID: 23482629, Jan. 2013*

37. T. Mizutani*, N. Neugebauer*, E.M. Putz*, N. Moritz, O. Simma, E. Zebedin-Brandl, D. Gotthardt, W. Warsch, E. Eckelhart, H.P. Kantner, U. Kalinke, S.Lienenklaus, S. Weiss, B. Strobl, M. Müller, V. Sexl and D. Stoiber. Conditional IFNAR1 ablation reveals distinct requirements of type I IFN signaling for NK cell maturation and tumor surveillance. ***OncoImmunology**, PMID:23170251, Oct. 2012*

38. E.M. Putz, C. Schuster and V. Sexl. Bcl-2: Live and let die. ***OncoImmunology**, PMID: 22934270, Aug. 2012*

39. E.M. Putz*, M. Prchal-Murphy*, O.A. Simma, F. Forster, X. Koenig, H. Stockinger, R.P. Piekorz, M. Freissmuth, M. Müller, V. Sexl and E. Zebedin-Brandl. PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes. ***PLoS ONE**, PMID: 22808277, Jul. 2012*

40. E.M. Putz, E. Zebedin and V. Sexl. STAT Transcription Factors: Controlling All Aspects of NK Cell Biology. (bookchapter, p. 187-204) in the book: Jak-Stat Signaling: From Basics to Disease, editors T. Decker and M. Müller; ***Springer**, Online: ISBN 978-3-7091-0891-8, Jun. 2012*

41. C. Schuster*, A. Berger*, M.A. Hoelzl, E.M. Putz, A. Frenzel, O. Simma, N. Moritz, A. Hoelbl, B. Kovacic, M. Freissmuth, M. Müller, A. Villunger, L. Müllauer, A.I. Schmatz, E. Porpaczy, U. Jäger, D. Stoiber and V. Sexl. The cooperating mutation or "second hit" determines the immunological visibility towards MYC-induced murine lymphomas. ***Blood**, PMID: 21878673, Aug. 2011*

42. A.A. Vitale, A.B. Pomilio, C.O. Cañellas, M.G. Vitale, E.M. Putz and J. Ciprian-Ollivier. In Vivo Long-Term Kinetics of Radiolabeled *N*,*N*-Dimethyltryptamine and Tryptamine. ***Journal of Nuclear Medicine**, PMID: 21622895, Jun. 2011*

43. O. Simma, E. Zebedin, N. Neugebauer, C. Schellack, A. Pilz, S. Chang-Rodriguez, K. Lingnau, E. Weisz, E.M. Putz, W.F. Pickl, T. Felzmann, M. Müller, T. Decker, V. Sexl and D. Stoiber. Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance. ***Cancer Research**, PMID: 19118004, Jan. 2009*

44. E. Zebedin, O. Simma, C. Schuster, E.M. Putz, S. Fajmann, W. Warsch, E. Eckelhart, D. Stoiber, E. Weisz, J.A. Schmid, W.F. Pickl, C. Baumgartner, P. Valent, R.P. Piekorz, M. Freissmuth and V. Sexl. Leukemic challenge unmasks a requirement for *PI3Kδ* in NK-cell-mediated tumor surveillance. ***Blood**, PMID: 18684865, Aug. 2008*

* … contributed equally